The Health Centrum
Welcome,         Profile    Billing    Logout  
 0 Trials 
2 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Balgos, Abundio A
ReCOV, NCT05084989: Safety, and Immunogenicity Study of the Recombinant Two-component COVID-19 Vaccine (CHO Cell)

Completed
2
948
RoW
Part1:Recombinant two-component COVID-19 vaccine (CHO cell), Part1: ReCOV, Part1: Placebo, Part2: Recombinant two-component COVID-19 vaccine (CHO cell), Part2: ReCOV, Part2: COVID-19 Vaccine, mRNA, Part2: COMIRNATY®
Jiangsu Rec-Biotechnology Co., Ltd.
COVID-19
08/22
02/23
Meng, fanyue
ReCOV, NCT05084989: Safety, and Immunogenicity Study of the Recombinant Two-component COVID-19 Vaccine (CHO Cell)

Completed
2
948
RoW
Part1:Recombinant two-component COVID-19 vaccine (CHO cell), Part1: ReCOV, Part1: Placebo, Part2: Recombinant two-component COVID-19 vaccine (CHO cell), Part2: ReCOV, Part2: COVID-19 Vaccine, mRNA, Part2: COMIRNATY®
Jiangsu Rec-Biotechnology Co., Ltd.
COVID-19
08/22
02/23

Download Options